217 related articles for article (PubMed ID: 12641861)
21. Estimated Cost Effectiveness of Influenza Vaccination for Emergency Medical Services Professionals.
Hubble MW; Renkiewicz GK
West J Emerg Med; 2021 Oct; 22(6):1317-1325. PubMed ID: 34787557
[TBL] [Abstract][Full Text] [Related]
22. Productivity loss outcomes and costs among patients with cholangiocarcinoma in the United States: an economic evaluation.
Parasuraman S; Thiel E; Park J; Teschemaker A
J Med Econ; 2023; 26(1):454-462. PubMed ID: 36883994
[TBL] [Abstract][Full Text] [Related]
23. The annual impact of seasonal influenza in the US: measuring disease burden and costs.
Molinari NA; Ortega-Sanchez IR; Messonnier ML; Thompson WW; Wortley PM; Weintraub E; Bridges CB
Vaccine; 2007 Jun; 25(27):5086-96. PubMed ID: 17544181
[TBL] [Abstract][Full Text] [Related]
24. [Anti-influenza vaccination for active persons (25-64 years): a cost-benefit study].
Levy E; Levy P
Rev Epidemiol Sante Publique; 1992; 40(5):285-95. PubMed ID: 1480805
[TBL] [Abstract][Full Text] [Related]
25. A systematic review and meta-analysis of the direct epidemiological and economic effects of seasonal influenza vaccination on healthcare workers.
Imai C; Toizumi M; Hall L; Lambert S; Halton K; Merollini K
PLoS One; 2018; 13(6):e0198685. PubMed ID: 29879206
[TBL] [Abstract][Full Text] [Related]
26. The effectiveness of vaccination against influenza in healthy, working adults.
Nichol KL; Lind A; Margolis KL; Murdoch M; McFadden R; Hauge M; Magnan S; Drake M
N Engl J Med; 1995 Oct; 333(14):889-93. PubMed ID: 7666874
[TBL] [Abstract][Full Text] [Related]
27. Influenza and Workplace Productivity Loss in Working Adults.
Van Wormer JJ; King JP; Gajewski A; McLean HQ; Belongia EA
J Occup Environ Med; 2017 Dec; 59(12):1135-1139. PubMed ID: 28759481
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.
Clements KM; Chancellor J; Nichol K; DeLong K; Thompson D
Value Health; 2011; 14(6):800-11. PubMed ID: 21914499
[TBL] [Abstract][Full Text] [Related]
29. Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review.
Blanchet Zumofen MH; Frimpter J; Hansen SA
Pharmacoeconomics; 2023 Mar; 41(3):253-273. PubMed ID: 36515814
[TBL] [Abstract][Full Text] [Related]
30. Influence of clinical case definitions with differing levels of sensitivity and specificity on estimates of the relative and absolute health benefits of influenza vaccination among healthy working adults and implications for economic analyses.
Nichol KL; Mendelman P
Virus Res; 2004 Jul; 103(1-2):3-8. PubMed ID: 15163481
[TBL] [Abstract][Full Text] [Related]
31. Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness.
Prosser LA; O'Brien MA; Molinari NA; Hohman KH; Nichol KL; Messonnier ML; Lieu TA
Pharmacoeconomics; 2008; 26(2):163-78. PubMed ID: 18198935
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
Luce BR; Nichol KL; Belshe RB; Frick KD; Li SX; Boscoe A; Rousculp MD; Mahadevia PJ
Vaccine; 2008 Jun; 26(23):2841-8. PubMed ID: 18462851
[TBL] [Abstract][Full Text] [Related]
33. Workplace influenza vaccination to reduce employee absenteeism: An economic analysis from the employers' perspective.
Verelst F; Beutels P; Hens N; Willem L
Vaccine; 2021 Apr; 39(14):2005-2015. PubMed ID: 33632564
[TBL] [Abstract][Full Text] [Related]
34. [Efficiency of influenza vaccination in the working population in Spain].
de Juanes JR; Cisterna R; Sanz J; Magaz S; Badia X
Gac Sanit; 2006; 20(2):101-7. PubMed ID: 16753086
[TBL] [Abstract][Full Text] [Related]
35. Absenteeism and Employer Costs Associated With Chronic Diseases and Health Risk Factors in the US Workforce.
Asay GR; Roy K; Lang JE; Payne RL; Howard DH
Prev Chronic Dis; 2016 Oct; 13():E141. PubMed ID: 27710764
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of influenza vaccination in working-age cancer patients.
Avritscher EB; Cooksley CD; Geraci JM; Bekele BN; Cantor SB; Rolston KV; Elting LS
Cancer; 2007 Jun; 109(11):2357-64. PubMed ID: 17457827
[TBL] [Abstract][Full Text] [Related]
37. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.
Ryan J; Zoellner Y; Gradl B; Palache B; Medema J
Vaccine; 2006 Nov; 24(47-48):6812-22. PubMed ID: 17034909
[TBL] [Abstract][Full Text] [Related]
38. A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac in the UK.
Das Gupta R; Guest JF
Pharmacoeconomics; 2002; 20(7):475-84. PubMed ID: 12093303
[TBL] [Abstract][Full Text] [Related]
39. [Assessment of efficacy and economic impact of an influenza vaccination campaign in the personnel of a health care setting].
Cella MT; Corona G; Tuccillo E; Franco G
Med Lav; 2005; 96(6):483-9. PubMed ID: 16983973
[TBL] [Abstract][Full Text] [Related]
40. Economic evaluation of vaccination against influenza in New Zealand.
Scott WG; Scott HM
Pharmacoeconomics; 1996 Jan; 9(1):51-60. PubMed ID: 10160087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
